Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Legend Biotech Corp
LEGN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$19.00
0.35
1.88%
Últ. Act.: Oct 20, 9:23 AM
$19.00
0.35
1.88%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Legend Biotech Financials
Legend Biotech (LEGN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Benzinga Newsdesk
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.
Avi Kapoor
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the
Benzinga Newsdesk
Earnings Scheduled For March 10, 2026
Benzinga Insights
Legend Biotech Q4 Earnings Summary & Key Takeaways
Benzinga Insights
